专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190218275A1 IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS 审中-公开
公开(公告)号：US20190218275A1
公开(公告)日：2019-07-18
申请号：US16226964
申请日：2018-12-20
申请人： University of Maryland, Baltimore , Gliknik Inc.
发明人： Scott E. STROME , Dan H. SCHULZE , David S. BLOCK , Henrik OLSEN
IPC分类号： C07K16/00 , C07K16/06 , C07K16/32 , C07K16/28 , C07K16/18 , G01N33/50
CPC分类号： C07K16/00 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K16/065 , C07K16/18 , C07K16/28 , C07K16/283 , C07K16/2863 , C07K16/32 , C07K2317/35 , C07K2317/41 , C07K2317/50 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2318/00 , C07K2319/00 , C07K2319/30 , G01N33/5047 , G01N2500/10 , Y02A50/412
摘要： IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases

2. 发明授权

US09957325B2 Synthetic antibody mimic peptides 有权
公开(公告)号：US09957325B2
公开(公告)日：2018-05-01
申请号：US14882436
申请日：2015-10-13
申请人： Formurex, Inc.
发明人： Xiaoling Li , Jerry Tsai , Bhaskara Rao Jasti , Hyun Joo , Yu Zheng , Dan Su , Sameer Sachdeva
IPC分类号： A61K38/00 , G01N33/74 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/00 , C07K7/08 , C07K2318/00 , G01N33/74 , G01N2333/71
摘要： The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins.

3. 发明申请

US20170283471A1 MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS 审中-公开
公开(公告)号：US20170283471A1
公开(公告)日：2017-10-05
申请号：US15621159
申请日：2017-06-13
申请人： President and Fellows of Harvard College
发明人： Adva Mechaly , Andrew J. McCluskey , R. John Collier
IPC分类号： C07K14/32 , C07K16/40 , C07K14/25 , C07K14/28 , C07K14/21 , C07K14/33 , C07K14/34 , C07K16/28 , C07K16/32
CPC分类号： C07K14/32 , C07K14/21 , C07K14/25 , C07K14/28 , C07K14/33 , C07K14/34 , C07K16/2863 , C07K16/32 , C07K16/40 , C07K2317/73 , C07K2318/00 , C07K2319/00 , C07K2319/33 , C07K2319/55 , C07K2319/75
摘要： We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells.

4. 发明申请

US20170226514A1 PREVENTION OF TUMOUR METASTASIS BY INHIBITION OF NECROPTOSIS 审中-公开
公开(公告)号：US20170226514A1
公开(公告)日：2017-08-10
申请号：US15503583
申请日：2015-08-11
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
发明人： Stefan OFFERMANNS , Boris STRILIC
IPC分类号： C12N15/115 , C07K2/00 , G01N33/50 , C07D417/06 , C07D403/06 , C07D409/12 , C07K16/40 , C12N15/113
CPC分类号： C12N15/115 , A61K31/4178 , A61K31/713 , A61K45/06 , C07D403/06 , C07D409/12 , C07D417/06 , C07K2/00 , C07K14/4702 , C07K14/525 , C07K14/7151 , C07K16/40 , C07K2317/76 , C07K2318/00 , C12N15/1137 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/141 , C12N2310/16 , C12N2310/531 , G01N33/5011 , A61K2300/00
摘要： The present invention relates to an inhibitor of necroptosis for use in preventing the metastasis of tumours. Further, the present invention relates to a method of preventing the metastasis of tumours by inhibiting necroptosis and to a method for modulating the transmigration of metastasising tumour cells through endothelium by modulating necroptosis as well as to an in-vitro method of identifying an inhibitor of necroptosis suitable as a lead compound and/or as a medicament for the prevention of tumour metastasis. Moreover, the present invention also relates to a method of identifying necroptotic and necrotic cells.

5. 发明申请

US20160355570A1 IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS 审中-公开
公开(公告)号：US20160355570A1
公开(公告)日：2016-12-08
申请号：US15199416
申请日：2016-06-30
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , GLIKNIK INC.
发明人： Scott E. Strome , Dan H. Schulze , David S. Block , Henrik Olsen
IPC分类号： C07K16/00 , C07K16/28 , C07K16/32
CPC分类号： C07K16/00 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K16/065 , C07K16/18 , C07K16/28 , C07K16/283 , C07K16/2863 , C07K16/32 , C07K2317/35 , C07K2317/41 , C07K2317/50 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2318/00 , C07K2319/00 , C07K2319/30 , G01N33/5047 , G01N2500/10 , Y02A50/412
摘要： IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

6. 发明申请

US20160052976A1 MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS 有权
公开(公告)号：US20160052976A1
公开(公告)日：2016-02-25
申请号：US14625386
申请日：2015-02-18
申请人： President and Fellows of Harvard College
发明人： Adva Mechaly , Andrew J. McCluskey , John R. Collier
IPC分类号： C07K14/32 , C07K16/40
CPC分类号： C07K14/32 , C07K14/21 , C07K14/25 , C07K14/28 , C07K14/33 , C07K14/34 , C07K16/2863 , C07K16/32 , C07K16/40 , C07K2317/73 , C07K2318/00 , C07K2319/00 , C07K2319/33 , C07K2319/55 , C07K2319/75
摘要： We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells.

7. 发明授权

US09079969B2 Non-natural MIC proteins 有权
标题翻译：非天然MIC蛋白
公开(公告)号：US09079969B2
公开(公告)日：2015-07-14
申请号：US14311130
申请日：2014-06-20
申请人： AvidBiotics Corp.
发明人： David W. Martin, Jr. , Steven R. Williams
IPC分类号： C07H21/02 , C07H21/04 , C07K14/47 , C07K14/74 , C07K14/00 , A61K38/00
CPC分类号： C07K14/473 , A61K38/00 , C07K14/70539 , C07K2318/00 , C07K2319/33 , Y02A50/389 , Y02A50/393
摘要： This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein.
摘要翻译：本发明描述了通过连接单价MICA或MICB蛋白（即它们的α1-α2平台结构域）的NKG2D结合部分可以激活NK细胞和某些T细胞以攻击特异性细胞靶细胞的可溶性，一价，非天然蛋白质分子，具体到目的细胞。 α1-α2结构域与已经被遗传修饰的异源α3结构域连续，直接或间接地结合到靶细胞的细胞外方面，从而作为靶向结构域。在α3结构域内产生非天然和非末端靶向基序的遗传修饰可以包括MIC蛋白质的一部分抗体，另一蛋白质分子或其部分，肽或非天然修饰的α3结构域。

8. 发明申请

US20150056185A1 IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS 有权
标题翻译：免疫球蛋白恒定区FC受体结合剂
公开(公告)号：US20150056185A1
公开(公告)日：2015-02-26
申请号：US14221148
申请日：2014-03-20
申请人： GLIKNIK INC. , UNIVERSITY OF MARYLAND, BALTIMORE
发明人： SCOTT E. STROME , DAN H. SCHULZE , DAVID S. BLOCK
IPC分类号： C07K16/18
CPC分类号： C07K16/00 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K16/065 , C07K16/18 , C07K16/28 , C07K16/283 , C07K16/2863 , C07K16/32 , C07K2317/35 , C07K2317/41 , C07K2317/50 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2318/00 , C07K2319/00 , C07K2319/30 , G01N33/5047 , G01N2500/10 , Y02A50/412
摘要： IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
摘要翻译： IVIG替代化合物衍生自免疫活性仿生物的重组和/或生物化学产生。然后在体外筛选这些置换化合物以评估每种替代化合物调节免疫功能的效率。选择特定的替代化合物用于进一步的体内验证和剂量/给药优化。最后，替代化合物用于治疗广泛的疾病，包括炎性和自身免疫性疾病。

9. 发明授权

US08796420B2 Non-natural MIC proteins 有权
标题翻译：非天然MIC蛋白
公开(公告)号：US08796420B2
公开(公告)日：2014-08-05
申请号：US13176601
申请日：2011-07-05
申请人： David W. Martin, Jr. , Steven R. Williams
发明人： David W. Martin, Jr. , Steven R. Williams
IPC分类号： A61K38/16 , C07K16/00 , A01N63/00 , C07K19/00 , C12N5/0783
CPC分类号： C07K14/473 , A61K38/00 , C07K14/70539 , C07K2318/00 , C07K2319/33 , Y02A50/389 , Y02A50/393
摘要： This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein.
摘要翻译：本发明描述了通过连接单价MICA或MICB蛋白（即它们的α1-α2平台结构域）的NKG2D结合部分可以激活NK细胞和某些T细胞以攻击特异性细胞靶细胞的可溶性，一价，非天然蛋白质分子，具体到目的细胞。 α1-α2结构域与已经被遗传修饰的异源α3结构域连续，直接或间接地结合到靶细胞的细胞外方面，从而作为靶向结构域。在α3结构域内产生非天然和非末端靶向基序的遗传修饰可以包括MIC蛋白质的一部分抗体，另一蛋白质分子或其部分，肽或非天然修饰的α3结构域。

10. 发明授权

US08680237B2 Immunoglobulin constant region FC receptor binding agents 有权
标题翻译：免疫球蛋白恒定区FC受体结合剂
公开(公告)号：US08680237B2
公开(公告)日：2014-03-25
申请号：US12602609
申请日：2008-05-30
申请人： Scott E. Strome , Dan H. Schulze , David S. Block , Henrik Olsen
发明人： Scott E. Strome , Dan H. Schulze , David S. Block , Henrik Olsen
IPC分类号： C07K1/00 , A61K35/14 , C07K16/00 , C12P21/08
CPC分类号： C07K16/00 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K16/065 , C07K16/18 , C07K16/28 , C07K16/283 , C07K16/2863 , C07K16/32 , C07K2317/35 , C07K2317/41 , C07K2317/50 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2318/00 , C07K2319/00 , C07K2319/30 , G01N33/5047 , G01N2500/10 , Y02A50/412
摘要： IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
摘要翻译： IVIG替代化合物衍生自免疫活性仿生物的重组和/或生物化学产生。然后在体外筛选这些置换化合物以评估每种替代化合物调节免疫功能的效率。选择特定的替代化合物用于进一步的体内验证和剂量/给药优化。最后，替代化合物用于治疗广泛的疾病，包括炎性和自身免疫疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式